It's been a quiet fall from grace for CSL Ltd (ASX: CSL) shares.
Once a market darling, the ASX biotech giant has slipped around 45% over the past 12 months and is now drifting near 52-week lows. Short-term issues have started to dominate headlines, and investor confidence has taken a hit.
But here's the big question: is this the kind of setup long-term investors wait for?
Image source: Getty Images
Softer performance, weak sentiment
CSL's latest half-year result helps explain the weak sentiment.
The company reported softer performance, with underlying profit declining and revenue slightly lower. A mix of policy changes, restructuring costs, and impairments weighed on the numbers — not exactly what investors wanted to see.
That's been enough to keep pressure on CSL shares.
But look a little deeper, and the story starts to shift. This doesn't look like a business in decline. It looks like a business in transition.
CSL remains a global leader in plasma therapies and vaccines, supplying critical treatments for chronic and rare diseases. These are not optional products. Demand is consistent, recurring, and largely immune to economic cycles.
That gives CSL a powerful defensive edge.
Foundations still strong
At the same time, momentum is quietly building again for CSL shares. Plasma collections are improving, margins in its core CSL Behring division are stabilising, and its vaccine arm, Seqirus, continues to add diversification and growth potential.
In other words, the foundations are still strong.
What we're seeing now is more of a reset — both in earnings and valuation — after a period of elevated expectations.
And that reset could be creating opportunity.
Margin pressure, integration risks
Of course, there are risks to consider.
CSL has faced ongoing margin pressure, integration challenges, and currency headwinds. If the earnings recovery takes longer than expected, or if costs remain elevated, the price of CSL shares could stay under pressure.
There's also the broader issue of market sentiment. Even high-quality healthcare stocks can fall out of favour when investors rotate into other sectors.
But the long-term thesis remains intact.
What next for CSL shares?
Encouragingly, analysts are backing a recovery.
Broker sentiment on CSL shares is broadly positive, with most maintaining buy or outperform ratings. The average 12-month price target sits around $214.00, suggesting potential upside of roughly 54% from current levels.
And some are even more bullish.
UBS has a buy rating and a $235 price target on CSL shares, implying a possible 69% upside over the next year. Some forecasts go further, tipping gains of up to 98%.
Foolish Takeaway
The bottom line? CSL shares may have lost their shine in the short term, but the underlying business hasn't.
For investors willing to look beyond the noise, this could be a rare chance to buy a world-class healthcare company at a significant discount.
